“Dialogue between government and industry for the creation of innovative drugs” was held on the 16th of Nov to exchange views on policy between Pharmaceutical industries and relevant ministers such as the Ministry of Health, Labor and Welfare and the Ministry of Education, Culture, Sports, Science and Technology. Governments interviewed pharmaceutical industries about future steps to strengthen innovation. There were ｍany opinions from the industries to call for environmental improvement which encourages innovations such as careful actions to the mid-year revision scheduled for April next year, preventing infectious diseases such as new coronavirus infections and Antimicrobial Resistance (AMR), and utilization of data and others.
The FPMAJ and the Japan Pharmaceutical Manufacturers Association (JPMA) requested, “since the drug price revisions continued to be strict, the mid-year revisions would have a massive impact on the industry, and we would like to ask for careful actions.”
Dr. Isao Teshirogi, President of FPMAJ, called for a government-led initiative, saying, “AMR’s therapeutic drug development system is weakening. It is necessary to take action for the next 5 to 10 years.” Taking the capital investment of the new influenza vaccine in the past as an example, he pointed out, “As the further use was left to the manufacturer, it is necessary to take action based on prior reflection.”
Joji Nakayama, President of JPMA, raised the issue that “the whole genome analysis of Japanese people has not progressed” and called for promoting the genome analysis business “I want it to be easy for pharmaceutical companies to use.”
At the government’s administrative reform promotion meeting “Autumn Administrative Business Review.” It was pointed out that the disclosure level of the total cost of products in the cost calculation method’s drug prices. However, “The authorities checked and disclosed the costs,” he explained.
Norihisa Tamura, Minister of Health, Labor and Welfare said, “We are aware of the concerns about the mid-year revision. Although there are strong opinions in the evaluation of innovation, it is important to balance the promotion of innovation and maintenance of national health insurance due to limited financial resources. I want to make sure that innovative new drug come out of Japan. ”
※掲載記事の無断転載を禁じます。
上記英訳記事のお問合せ先
株式会社シーエムプラス：https://cm-plus.co.jp/
